

**Table 2:** Serum metabolic parameters at baseline and after three months of drug treatment of the 44 patients with mixed dyslipidemia not at treatment goal despite treatment with simvastatin 10-40 mg or atorvastatin 10-20 mg or rosuvastatin 5-10 mg. These patients were randomized to switching to high-dose rosuvastatin or add-on-statin nicotinic acid or add-on-statin fenofibrate. The primary end point was between group difference in changes of 25(OH)VitD serum levels after three months of treatment. Serum 25(OH)VitD levels did not significantly change in any group and no significant difference between groups was found

	Baseline	3 months	Change %
<b>TGs (mg/dL)</b>			
Switch to high-dose rosuvastatin	190 (173-210)	152 (140-184)	-20 <sup>‡</sup>
Add-on-statin ER-NA/LRPT	213 (190-254)	128 (119-178)	-40 <sup>‡,§</sup>
Add-on-statin fenofibrate	210 (189-260)	142 (118-170)	-32 <sup>‡,§</sup>
<b>HDL-C, mg/dL (mmol/L)</b>			
Switch to high-dose rosuvastatin	50±9	51±10	+2 <sup>†</sup>
Add-on-statin ER-NA/LRPT	47±12	53±11	+13 <sup>†,§,#</sup>
Add-on-statin fenofibrate	45±11	48±10	+7 <sup>‡,§</sup>
<b>LDL-C (mg/dL)</b>			
Switch to high-dose rosuvastatin	121±40	93±24	-23 <sup>‡,#</sup>
Add-on-statin ER-NA/LRPT	115±35	93±34	-19 <sup>‡,#</sup>
Add-on-statin fenofibrate	112±32	116±33	+4
<b>Non-HDL-C (mg/dL)</b>			
Switch to high-dose rosuvastatin	157±40	123±23	-22 <sup>‡,#</sup>
Add-on-statin ER-NA/LRPT	156±37	117±34	-25 <sup>‡,#</sup>
Add-on-statin fenofibrate	155±34	144±36	-7 <sup>†</sup>
<b>eGFR (mL/min/1.73 m<sup>2</sup>)</b>			
Switch to high-dose rosuvastatin	86±28	85±26	-0.01
Add-on-statin ER-NA/LRPT	90±29	90±26	0
Add-on-statin fenofibrate	95±29	99±27	+0.04
<b>25(OH)VitD (ng/ml)</b>			
Switch to high-dose rosuvastatin	16.8 (3.2-37)	16.0 (7.9-51.6)	-4.7
Add-on-statin ER-NA/LRPT	12.8 (2.0-54.8)	10.9 (2.4-34)	-14.8
Add-on-statin fenofibrate	14.5 (1.0-42)	16.4 (4.4-30.4)	+13.0

TGs: triglycerides, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, non-HDL-C is calculated as TC minus HDL-C, TC: total cholesterol, eGFR: estimated glomerular filtration rate, 25(OH)Vit D: 25-hydroxy vitamin D, <sup>†</sup>p < 0.01 versus baseline levels, <sup>‡</sup>p < 0.001 versus baseline levels, <sup>§</sup>p < 0.01 versus the switch to rosuvastatin 40 mg group, <sup>#</sup>p < 0.01 versus the add-on-statin fenofibrate group.